Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and Novo ...

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...

Schumacher is stepping down by mutual agreement on Saturday, before leaving the company on May 31. Japanese trading-house stocks rose sharply after Warren Buffett said Berkshire Hathaway's stakes in ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

UnitedHealth Group, Alphabet, Hims & Hers Health, Salesforce, and Johnson & Johnson are the five Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. These companies had ...

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of ...

Discover how Hims & Hers Health closed 2024 with strong growth, expanding weight-loss solutions, and innovation-focused investments in ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...